Determination of the potency of a novel saw palmetto supercritical CO₂ extract (SPSE) for 5α-reductase isoform II inhibition using a cell-free in vitro test system

References

• ShirakawaTOkadaHAcharyaBMessenger RNA levels and enzyme activities of 5 alpha-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissueProstate200458334014673950
   PubMed Web of Science ®Google Scholar
• DélosSIehléCMartinPMRaynaudJPInhibition of the activity of ‘basic’ 5α-reductase (type 1) detected in DU 145 cells and expressed in insect cellsJ Steroid Biochem Mol Biol1994483473528142312
   PubMed Web of Science ®Google Scholar
• BoudonCLobaccaroJMLumbrosoS5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates – effect of finasteride (Proscar), a 5 alpha-reductase inhibitorCell Mol Biol (Noisy-le-Grand)199541100710158747081
   PubMed Web of Science ®Google Scholar
• LeeJAndrioleGAvinsARedesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasiaClin Trials2009662863620007408
   PubMed Web of Science ®Google Scholar
• ComhaireFMahmoudAPreventing diseases of the prostate in the elderly using hormones and nutriceuticalsAging Male2004715516915672940
   PubMedGoogle Scholar
• LaydnerHKOliveiraPOliveiraCRPhosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic reviewBJU Int20111071104110920883484
   PubMed Web of Science ®Google Scholar
• BecharaACasabeARodriguez BaigorriGCobrerosCEffectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd studyJ Sex Med20141149850524224728
   PubMed Web of Science ®Google Scholar
• FalahatkarSMokhtariGPourrezaFAsgariSAKamranANCelecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled studyUrology20087281381618692876
   PubMed Web of Science ®Google Scholar
• ArakiTYokoyamaTKumonHEffectiveness of a nonsteroidal anti-inflammatory drug for nocturia on patients with benign prostatic hyperplasia: a prospective non-randomized study of loxoprofen sodium 60 mg once daily before sleepingActa Med Okayama200458454915157011
   PubMed Web of Science ®Google Scholar
• KahokehrAVatherRNixonAHillAGNon-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trialsBJU Int201311130431123356748
   PubMed Web of Science ®Google Scholar
• EdwardsJLDiagnosis and management of benign prostatic hyperplasiaAm Fam Physician2008771403141018533373
   PubMed Web of Science ®Google Scholar
• AllkanjariOVitaloneAWhat do we know about phytotherapy of benign prostatic hyperplasia?Life Sci2015126425625703069
   PubMed Web of Science ®Google Scholar
• AbeMItoYSuzukiAOnoueSNoguchiHYamadaSIsolation and pharmacologic characterization of fatty acids from saw palmetto extractAnal Sci20092555355719359798
   PubMed Web of Science ®Google Scholar
• ScaglioneFLuciniVPannacciMCaronnoALeoneCComparison of the potency of different brands of Serenoa repens extract on 5α-reductase types I and II in prostatic co-cultured epithelial and fibroblast cellsPharmacology20088227027518849646
   PubMed Web of Science ®Google Scholar
• ScaglioneFLuciniVPannacciMDugnaniSLeoneCComparison of the potency of 10 different brands of Serenoa repens extractsEur Rev Med Pharmacol Sci20121656957422774395
   PubMed Web of Science ®Google Scholar
• BentSKaneCShinoharaKSaw palmetto for benign prostatic hyperplasiaN Engl J Med200635455756616467543
   PubMed Web of Science ®Google Scholar
• LogTSerenoa repens in benign prostatic hyperplasiaTidsskr Nor Laegeforen200812812931294 Norwegian18511974
   PubMedGoogle Scholar
• MacDonaldRTacklindJWRutksIWiltTJSerenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic reviewBJU Int20121091756176122551330
   PubMed Web of Science ®Google Scholar
• BarryMJMelethSLeeJYEffect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trialJAMA20113061344135121954478
   PubMed Web of Science ®Google Scholar
• PaisPPotency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5α-reductase IIAdv Ther20102755556320623347
   PubMed Web of Science ®Google Scholar
• ReichertWHarmannRWJoseJStable expression of the human 5α-reductase isoenzymes type I and type II in HEK293 cells to identify dual and selective inhibitorsJ Enzyme Inhib200116475311496834
   PubMed Web of Science ®Google Scholar
• AnderssonSRussellDWStructural and biochemical properties of cloned and expressed human and rat steroid 5α-reductasesProc Natl Acad Sci U S A199087364036442339109
   PubMed Web of Science ®Google Scholar
• HabibFKRossMHoCKLyonsVChapmanKSerenoa repens (Permixon) inhibits the 5α-reductase activity of human prostate cancer cell lines without interfering with PSA expressionInt J Cancer200511419019415543614
   PubMed Web of Science ®Google Scholar
• WiltTJIshaniARutksIMacDonaldRPhytotherapy for benign prostatic hyperplasiaPublic Health Nutr2000345947211276294
   PubMedGoogle Scholar
• GerberGSKuznetsovDJohnsonBCBursteinJDRandomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract infectionsUrology20015896096411744467
   PubMed Web of Science ®Google Scholar
• SuterASallerRRiediEHeinrichMImproving BPH symptoms and sexual dysfunctions with a saw palmetto preparation? Results from a pilot trialPhytother Res20132721822622522969
   PubMed Web of Science ®Google Scholar
• GiulianelliRPecoraroSSepeGMulticentre study on the efficacy and tolerability of an extract of Serenoa repens in patients with chronic benign prostate conditions associated with inflammationArch Ital Urol Androl201284949822908779
   PubMedGoogle Scholar
• AvinsALLeeJYMeyersCMBarryMJCAMUS Study GroupSafety and toxicity of saw palmetto in the CAMUS trialJ Urol20131891415142023063633
   PubMed Web of Science ®Google Scholar
• PerryRMilliganGAndersonPGillonAWhiteMReal-world use of Permixon in benign prostatic hyperplasia–determining appropriate monotherapy and combination treatmentAdv Ther20122953855022644964
   PubMed Web of Science ®Google Scholar
• MinutoliLBittoASquadritoFSerenoa repens, lycopene and selenium: a triple therapeutic approach to manage benign prostatic hyperplasiaCurr Med Chem2013201306131223432584
   PubMed Web of Science ®Google Scholar
• HizliFUygurMCA prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasiaInt Urol Nephrol20073987988617203353
   PubMed Web of Science ®Google Scholar
• LoweFCKuJCPhytotherapy in treatment of benign prostatic hyperplasia: a critical reviewUrology19964812208693632
   PubMed Web of Science ®Google Scholar
• WiltTIshaniAMacDonaldRSerenoa repens for benign prostatic hyperplasiaCochrane Database Syst Rev20023CD00142312137626
   PubMedGoogle Scholar
• BookerASuterAKrnjicAA phytochemical comparison of saw palmetto products using gas chromatography and 1H nuclear magnetic resonance spectroscopy metabolomic profilingJ Pharm Pharmacol20146681182224417505
   PubMed Web of Science ®Google Scholar